{"component": "definition", "props": {"groups": [{"samples": [{"hash": "ingeYLFFbsO", "uri": "/contracts/ingeYLFFbsO#targeting", "label": "Asset Contribution Agreement (Allogene Therapeutics, Inc.)", "score": 34.8343582153, "published": true}, {"hash": "ib3o6qlxVJZ", "uri": "/contracts/ib3o6qlxVJZ#targeting", "label": "License Agreement (Allogene Therapeutics, Inc.)", "score": 30.3442840576, "published": true}, {"hash": "hWAQrrYmJk", "uri": "/contracts/hWAQrrYmJk#targeting", "label": "License Agreement (Cellectis S.A.)", "score": 30.3114299774, "published": true}], "snippet_links": [{"key": "relationship-between", "type": "clause", "offset": [33, 53]}, {"key": "the-target", "type": "clause", "offset": [110, 120]}, {"key": "a-portion", "type": "definition", "offset": [125, 134]}], "snippet": "means, when used to describe the relationship between a molecule and a Target, that the molecule (a) binds to the Target (or a portion thereof) and (b) is designed or being developed to exert its biological effect in whole or in part through binding to such Target (or such portion thereof).", "size": 22, "hash": "2737b8af29c372734c34756e647bd269", "id": 1}, {"samples": [{"hash": "2hQpDZGFmFG", "uri": "/contracts/2hQpDZGFmFG#targeting", "label": "Joint Venture Agreement", "score": 36.5126647949, "published": true}, {"hash": "6cpG9OzxjWM", "uri": "/contracts/6cpG9OzxjWM#targeting", "label": "Crispr Ip Contribution Agreement", "score": 31.3408622742, "published": true}, {"hash": "cejWDvdh5CR", "uri": "/contracts/cejWDvdh5CR#targeting", "label": "Joint Venture Agreement (CRISPR Therapeutics AG)", "score": 27.7652301788, "published": true}], "snippet_links": [{"key": "excluded-target", "type": "definition", "offset": [222, 237]}, {"key": "covered-target", "type": "definition", "offset": [243, 257]}, {"key": "guide-rna", "type": "definition", "offset": [284, 293]}], "snippet": "means editing, engineering or modulating (including by means of gene knock-out, gene tagging, gene disruption, gene mutation, gene insertion, gene deletion, gene activation, gene silencing or gene knock-in) a Target or an Excluded Target or a Covered Target by means of hybridizing a guide RNA of the CRISPR/Cas Technology to such Target or Excluded Target or Covered Target.", "size": 11, "hash": "0d8e8f0156510ae8f1228e53eb064099", "id": 2}, {"samples": [{"hash": "b1GlbQJi6gp", "uri": "/contracts/b1GlbQJi6gp#targeting", "label": "License Agreement (CytomX Therapeutics, Inc.)", "score": 29.8459949493, "published": true}, {"hash": "Jckfm8G6w", "uri": "/contracts/Jckfm8G6w#targeting", "label": "Research Collaboration Agreement (CytomX Therapeutics, Inc.)", "score": 26.7494869232, "published": true}, {"hash": "hTHrx0EV42k", "uri": "/contracts/hTHrx0EV42k#targeting", "label": "Research Collaboration Agreement (CytomX Therapeutics, Inc.)", "score": 26.7385349274, "published": true}], "snippet_links": [{"key": "relationship-between", "type": "clause", "offset": [57, 77]}, {"key": "mechanism-of-action", "type": "clause", "offset": [141, 160]}, {"key": "the-target", "type": "clause", "offset": [186, 196]}, {"key": "a-portion", "type": "definition", "offset": [201, 210]}], "snippet": "or \u201cTargeted\u201d means, when used as a verb to describe the relationship between a molecule and a Target, where the molecule\u2019s primary intended mechanism of action requires that it bind to the Target (or a portion thereof).", "size": 9, "hash": "62df3607669a2eaf8ba82fa6bc2e73bc", "id": 3}, {"samples": [{"hash": "toyNMkJhal", "uri": "/contracts/toyNMkJhal#targeting", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 34.1444206238, "published": true}, {"hash": "8wkFXVcAmCH", "uri": "/contracts/8wkFXVcAmCH#targeting", "label": "Development and Marketing Agreement", "score": 27.0520191193, "published": true}, {"hash": "h4IzP3EHexR", "uri": "/contracts/h4IzP3EHexR#targeting", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 24.5646820068, "published": true}], "snippet_links": [{"key": "with-respect-to-an", "type": "clause", "offset": [7, 25]}, {"key": "target-gene", "type": "definition", "offset": [38, 49]}, {"key": "the-expression", "type": "definition", "offset": [79, 93]}], "snippet": "means, with respect to an siRNA and a target gene, that such siRNA antagonizes the expression of the messenger RNA of such target gene, and with respect to a product and a target gene, that such product contains an siRNA that antagonizes the expression of the messenger RNA of such target gene.", "size": 6, "hash": "08abfc73e89484eaed3a3b7943a5b3c0", "id": 4}, {"samples": [{"hash": "35u6E2ZesLa", "uri": "https://clearinghouse-umich-production.s3.amazonaws.com/media/doc/104820.pdf", "label": "clearinghouse-umich-production.s3.amazonaws.com", "score": 12.2093191147, "published": false}, {"hash": "klKd9RdKYRE", "uri": "https://nationalfairhousing.org/wp-content/uploads/2019/03/FINAL-Exhibit-A-3-18.pdf", "label": "nationalfairhousing.org", "score": 8.3388090134, "published": false}, {"hash": "hie6x3Bn2iT", "uri": "https://www.aclu.org/sites/default/files/field_document/final_exhibit_a.pdf", "label": "www.aclu.org", "score": 7.6050648689, "published": false}], "snippet_links": [{"key": "selection-tools", "type": "clause", "offset": [26, 41]}], "snippet": "means the use of Audience Selection Tools by advertisers to include or exclude users in a potential audience for paid advertisements.", "size": 3, "hash": "d0f0704ed075c3e0c1693c878494bf98", "id": 5}, {"samples": [{"hash": "aBx1KsZritO", "uri": "/contracts/aBx1KsZritO#targeting", "label": "License Agreement (Signal Genetics, Inc.)", "score": 26.0088977814, "published": true}, {"hash": "8POtdGTvhq2", "uri": "/contracts/8POtdGTvhq2#targeting", "label": "License Agreement (Signal Genetics, Inc.)", "score": 25.918548584, "published": true}, {"hash": "3X5WloVrOcm", "uri": "https://investors.viridiantherapeutics.com/static-files/5a7c5afd-8aff-4663-a989-84585aa18114", "label": "investors.viridiantherapeutics.com", "score": 10.0171117783, "published": false}], "snippet_links": [{"key": "relationship-between", "type": "clause", "offset": [33, 53]}, {"key": "lna-compound", "type": "definition", "offset": [57, 69]}, {"key": "for-purposes-of-this-section", "type": "clause", "offset": [235, 263]}, {"key": "for-clarity", "type": "clause", "offset": [292, 303]}], "snippet": "means, when used to describe the relationship between an LNA Compound and a Target, that such LNA Compound (a) is [*] to such Target and (b) is designed or being developed to exert its biological effect through binding to such Target. For purposes of this Section 1.67, \u201c[*]\u201d means that [*]. For clarity, an LNA Compound that is [*] to a Target may be [*].", "size": 3, "hash": "f8c8532b9390bf2e2df56f1cef5d1c75", "id": 6}, {"samples": [{"hash": "gym3iySCjzY", "uri": "/contracts/gym3iySCjzY#targeting", "label": "Strategic Collaboration, Option and License Agreement", "score": 30.3408622742, "published": true}, {"hash": "2fcTrAnDc6t", "uri": "/contracts/2fcTrAnDc6t#targeting", "label": "Strategic Collaboration, Option and License Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 27.1245727539, "published": true}], "snippet_links": [], "snippet": "means [***] a Target or the [***] thereof.", "size": 3, "hash": "f219bc13942d1d912bf2da91a31d514a", "id": 7}, {"samples": [{"hash": "1Ycgan5AbCP", "uri": "https://www.asc.uw.edu.pl/wp-content/uploads/2020/03/egazmin-wst%C4%99pny-2019-wersja-A_July-4.pdf", "label": "www.asc.uw.edu.pl", "score": 9.751540184, "published": false}, {"hash": "3GVpamwaKpH", "uri": "https://www.asc.uw.edu.pl/wp-content/uploads/2020/03/egazmin-wst%C4%99ny-wersja-B-July-4.pdf", "label": "www.asc.uw.edu.pl", "score": 9.751540184, "published": false}], "snippet_links": [], "snippet": "as used here means:", "size": 2, "hash": "a759dc25b958c750a904f8fab9ee4907", "id": 8}, {"samples": [{"hash": "bQl5bBBd7sn", "uri": "/contracts/bQl5bBBd7sn#targeting", "label": "Strategic Collaboration and License Agreement (CRISPR Therapeutics AG)", "score": 30.5715255737, "published": true}, {"hash": "fHypfY8lejL", "uri": "https://crisprtx.gcs-web.com/static-files/83b5d3fb-fcd7-43bf-8d9f-fc29207db0af", "label": "crisprtx.gcs-web.com", "score": 9.9938402176, "published": false}], "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [54, 69]}], "snippet": "means [***] a Target or [***] thereof; provided, that with respect to [***], Targeting means [***].", "size": 2, "hash": "6d52f88b769767318adfca90197c2235", "id": 9}, {"samples": [{"hash": "baqfY5Z1O1g", "uri": "/contracts/baqfY5Z1O1g#targeting", "label": "Collaborative Research and License Agreement (Legend Biotech Corp)", "score": 31.4065704346, "published": true}, {"hash": "7tQsKBQW59i", "uri": "/contracts/7tQsKBQW59i#targeting", "label": "Collaborative Research and License Agreement (Legend Biotech Corp)", "score": 31.3627643585, "published": true}], "snippet_links": [], "snippet": "or \u201cTargeted\u201d means, when used as a verb, [***].", "size": 2, "hash": "b27597d37df8f4430f1c047fe4d8c027", "id": 10}], "next_curs": "ClYSUGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjILEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiISdGFyZ2V0aW5nIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Targeting", "snippet": "means, when used to describe the relationship between a molecule and a Target, that the molecule (a) binds to the Target (or a portion thereof) and (b) is designed or being developed to exert its biological effect in whole or in part through binding to such Target (or such portion thereof).", "size": 76, "id": "targeting", "examples": ["The Director of the Financial Crimes Enforcement Network, U.S. Department of Treasury (\u201cFinCEN\u201d) issued a Geographic <strong>Targeting</strong> Order (as amended from time to time, the \u201cFinCen Order\u201d) requiring title insurance companies, subsidiaries and agents (each, a \u201cCovered Business\u201d), to identify (among other things) the true owners of entities that purchase residential real estate in certain transactions covered by the FinCen Order.", "If Closing Agent is required to comply with the U.S. Treasury Department\u2019s 541 Financial Crimes Enforcement Network (\u201cFinCEN\u201d) Geographic <strong>Targeting</strong> Orders (\u201cGTOs\u201d), then Buyer 542 shall provide Closing Agent with the information related to \u2587\u2587\u2587\u2587\u2587 and the transaction contemplated by this 543 Contract that is required to complete IRS Form 8300, and Buyer consents to Closing Agent\u2019s collection and 544 report of said information to IRS.", "Reference: BMD-ARS-6190 / BMD-ARS-6191 / BMD-ARS-6195 / BMD-ARS-6192 / BMD- ARS-6933 / BMD-ARS-6934 The user shall be able to add a table to a document with the Critical Assets and Areas that could be impacted by Threat BMs with the following information: for each Critical Asset/Area the name, the Threat BM Types and the Warhead Types and whether or not the BM <strong>Targeting</strong> Strategy was taken into account for the calculation."], "related": [["screening", "Screening", "Screening"], ["target-population", "Target Population", "Target Population"], ["biological-diversity", "Biological diversity", "Biological diversity"], ["hiv", "HIV", "HIV"], ["antibody", "Antibody", "Antibody"]], "related_snippets": [], "updated": "2025-08-06T06:32:10+00:00"}, "json": true, "cursor": ""}}